References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc. 2002;288:321–33.
- Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelli MT, Andrade S, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004; 104: 1042–50
- Travers C, O'Neill SM, Khoo S-K, King R. Hormones down under: hormone therapy use after the Women's Health Initiative. Aust NZ J Obstet Gynecol. 2006; 46: 330–5
- Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the million Women Study. www.thelancet.com. Published online 19 April, 2007; DOI: 10.1016/S0140-6736(07)60534-0.
- Lacey JV, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP diet and health study cohort. J Natl Cancer Inst. 2006; 98: 1397–405
- LaVecchia C. Estrogen-progestogen replacement therapy and ovarian cancer: an update. Eur J Cancer Prev. 2006; 15: 490–2
- Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand. 2004; 83: 783–95
- Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc. 2002; 288: 334–41
- Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 2002; 94: 497–504
- Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The Women's Health Initiative Randomized Trial. J Am Med Assoc. 2003; 290: 1739–48
- Recommendations for estrogen and progestogen use in peri- and post-menopausal women: October 2004 position statement of The North American Menopause Society. Menopause. 2004;11:589–600.
- Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356: 1670–4